Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.
about
Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging.The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene deliveryGenetic engineering with T cell receptorsHematopoietic stem cell engineering at a crossroadsCAR therapy: the CD19 paradigmAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersVirus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaUnderstanding the pharmacological properties of a metabolic PET tracer in prostate cancerATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imagingIntercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.Highly conserved RNA sequences that are sensors of environmental stress.Development of improved adenosine deaminase retroviral vectors.Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expressionProtein-protein interactions monitored in mammalian cells via complementation of beta -lactamase enzyme fragments.Construction of retroviral vectors with improved safety, gene expression, and versatility.Gammaretroviral vectors: biology, technology and applicationFrequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectorsTolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.Imaging transgene activity in vivo.CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectorsActivated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Gene transfer to human cells using retrovirus vectors produced by a new polytropic packaging cell lineInducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland.Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapyPersistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen.Tolerance to MHC class II disparate allografts through genetic modification of bone marrow.Insertional gene activation by lentiviral and gammaretroviral vectors.Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escapeManufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
P2860
Q24523051-084991A4-D6A1-4834-BA56-E59D856C4A60Q24804110-68C39D3F-8195-4E9A-A545-7B1CB2677560Q26995677-663D2140-9F3C-4325-B107-801FDFE0EA3AQ27001570-0562B2C2-8143-4B64-8743-7D984E573170Q28081642-6A3F5F97-AFAE-489B-AFD6-46626E63A1DFQ28551080-A1AC453B-D750-4116-9037-0A74BA128FF9Q29622835-BCEE4FCC-2801-469B-A984-CF2B4F45BA1DQ33665586-06DBEDB1-1B3A-484B-A7EF-19C67D5FAEC4Q33738298-90708037-7500-4AD4-8113-DF12924E6B4CQ33757055-78E9C66B-745C-46E9-AC1D-74834A8AB71BQ33781775-1C196FEF-A085-477B-AC63-A7C465EFEC23Q33782258-10BEFFCB-FB20-4684-8C26-B9FC33DA06C5Q33896804-65206A7E-35A7-473D-B72D-2B75175E14BFQ34007762-F313FF01-AD3B-49E1-AE78-934AE4641DBCQ34018186-94144B7B-5CAC-4E4C-835D-B363A7250BE0Q34018553-6CE318EE-C8A7-4253-B0BB-842176293B09Q34069096-85378AED-A8B4-4321-A788-9EFCB0610C0BQ34223822-C1689492-8B6C-45FD-8394-F0A75F849C2BQ34331185-FD041AF9-A89D-4BC8-9456-72D105446552Q34361879-8D5B832D-E478-4D48-B952-67508BA1B058Q34597429-A0FCADDA-BD86-4C20-BAD0-97F58F7B5B0AQ34667972-78D545F7-435F-4263-B85E-79533A1AB19EQ34715929-2974DB28-38A9-41E8-93DB-AD7553E7C614Q35222179-95A3749F-E514-4046-9A2F-DDD8A248BCCFQ35399334-8A02FF12-A42D-478D-82D5-1AF28920C5BFQ35506724-B5E54298-FDF5-46C7-9AF4-96D0382BF9D0Q35877585-B1BCB2A1-8861-4036-BB58-A8D061910FE4Q35887352-4E44C408-0C0F-4A9D-9756-F02DB853EB00Q36325197-D8C29954-A9FC-43C4-97F4-C701FDF45612Q36367841-76AC2E0D-9101-491C-B981-731A2BBF0BE9Q36368492-65AF72A3-1022-4541-A334-B1AE62857510Q36370817-8B47C165-2503-4A5B-B69F-B1A20D7084FBQ36404076-3C32B970-3954-4696-BFFD-C0C46EB00256Q36438003-CE3333D6-7ADA-4E45-89AF-35D06AD6AD7DQ36548693-16B554A4-7F65-48D2-A699-6B4C68EBB862Q36651903-AC06E0DF-4029-4000-A855-9AA2C54C8CAEQ36836700-40A4334F-C745-4CFB-8136-D61B170483EEQ37033273-A7D547C3-2A47-4A1D-B60B-8B03F0CC6416Q37137932-F2C3351C-4620-4F75-AC82-623CD10224FBQ37196769-E8C9EA14-CCEF-47FB-B6F8-3E957B4E2892
P2860
Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Effects of retroviral vector d ...... th genetically modified cells.
@ast
Effects of retroviral vector d ...... th genetically modified cells.
@en
Effects of retroviral vector d ...... th genetically modified cells.
@nl
type
label
Effects of retroviral vector d ...... th genetically modified cells.
@ast
Effects of retroviral vector d ...... th genetically modified cells.
@en
Effects of retroviral vector d ...... th genetically modified cells.
@nl
prefLabel
Effects of retroviral vector d ...... th genetically modified cells.
@ast
Effects of retroviral vector d ...... th genetically modified cells.
@en
Effects of retroviral vector d ...... th genetically modified cells.
@nl
P2093
P2860
P356
P1476
Effects of retroviral vector d ...... th genetically modified cells.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.15.6733
P407
P577
1995-07-01T00:00:00Z